Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) is on recovery track with 33.66% gain from a 1-year low price of $8.29. The company lost -2.81% to attain the price of $11.08 on 01/11/2019. Throughout the recent session, the prices were hovering between $11.02 and $11.4725. These shares are 100.45% off its target price of $22.21 and the current market capitalization stands at $715.1M. The recent change has given its price a -13.54% deficit over SMA 50 and -38.38% deficit over its 52-week high. The stock witnessed -13.77% declines, -16.75% declines and -15.68% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found DRNA’s volatility during a week at 5.2% and during a month it has been found around 8.92%.Dicerna Pharmaceuticals, Inc. (DRNA) Top Holders
Institutional investors currently hold around $607 million or 92.7% in DRNA stock. Look at its top three institutional owners. Bain Capital Life Sciences Investors, Llc owns $98.95 million in Dicerna Pharmaceuticals, Inc., which represents roughly 13.84% of the company’s market cap and approximately 16.3% of the institutional ownership. Similar statistics are true for the second largest owner, Bridger Management, Llc, which owns 5,530,028 shares of the stock are valued at $61.27 million. The third largest holder is Rtw Investments, Lp, which currently holds $60.51 million worth of this stock and that ownership represents nearly 8.46% of its market capitalization.Dicerna Pharmaceuticals, Inc. 13F Filings
At the end of September reporting period, 58 institutional holders increased their position in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) by some 9,992,544 shares, 30 decreased positions by 1,299,786 and 16 held positions by 43,498,124. That puts total institutional holdings at 54,790,454 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 1,993,844 shares while 10 institutional investors sold out their entire positions totaling 511,288 shares.Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Insider Trades
Multiple company employees have indulged in significant insider trading. Dicerna Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Halak Brian K has sold 335,000 shares of Dicerna Pharmaceuticals, Inc. (DRNA) in trading session dated Nov. 06, 2018. These shares are worth $4,465,550 and were traded at $13.33 each. The SEC filing shows that Halak Brian K performed a sale of 565,000 shares. The 10% Owner disposed these shares by way of transaction on Nov. 01, 2018. The company’s shares were given away at $13.66 per share worth to an income of some $7,717,900 on account of Halak Brian K.
Director, Halak Brian K, sold 564,300 common shares of Dicerna Pharmaceuticals, Inc. (DRNA) in the open market. In a transaction dated Nov. 01, 2018, the shares were put up for sale at an average price of $13.66, raking in a sum of $7,708,338. After this sale, 2,940,685 common shares of DRNA are directly owned by the insider, with total stake valued at $32,582,790.
In the transaction dated Sep. 05, 2018, the great number of shares disposed came courtesy the Chief Business Officer; Weissman James B disposed a total of 2,301 shares at an average price of $17.5, amounting to approximately $40,268. The insider now directly owns 24,480 shares worth $271,238.Dicerna Pharmaceuticals, Inc. (DRNA) Analyst Guide
Several analysts have released their opinion on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), with 3 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation.